220 related articles for article (PubMed ID: 24780647)
1. Specific inhibitory effects of the NO donor MAHMA/NONOate on human platelets.
Kobsar A; Simonis S; Klinker E; Koessler A; Kuhn S; Boeck M; Koessler J
Eur J Pharmacol; 2014 Jul; 735():169-76. PubMed ID: 24780647
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
3. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
4. Decreasing phosphodiesterase 5A activity contributes to platelet cGMP accumulation during storage of apheresis-derived platelet concentrates.
Kobsar A; Putz E; Yilmaz P; Weinig E; Boeck M; Koessler J
Transfusion; 2014 Apr; 54(4):1008-14. PubMed ID: 23909451
[TBL] [Abstract][Full Text] [Related]
5. Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein.
Sabetkar M; Naseem KM; Tullett JM; Friebe A; Koesling D; Bruckdorfer KR
Nitric Oxide; 2001 Jun; 5(3):233-42. PubMed ID: 11384196
[TBL] [Abstract][Full Text] [Related]
6. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
7. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies.
Aktas B; Utz A; Hoenig-Liedl P; Walter U; Geiger J
Stroke; 2003 Mar; 34(3):764-9. PubMed ID: 12624305
[TBL] [Abstract][Full Text] [Related]
8. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
9. Sodium azide, a bacteriostatic preservative contained in commercially available laboratory reagents, influences the responses of human platelets via the cGMP/PKG/VASP pathway.
Russo I; Del Mese P; Viretto M; Doronzo G; Mattiello L; Trovati M; Anfossi G
Clin Biochem; 2008 Mar; 41(4-5):343-9. PubMed ID: 18022387
[TBL] [Abstract][Full Text] [Related]
10. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
[TBL] [Abstract][Full Text] [Related]
11. Platelet inhibitory effects of the nitric oxide donor drug MAHMA NONOate in vivo in rats.
Homer KL; Wanstall JC
Eur J Pharmacol; 2003 Dec; 482(1-3):265-70. PubMed ID: 14660031
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet effects of caffeic acid due to Ca(2+) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation.
Lee DH; Kim HH; Cho HJ; Bae JS; Yu YB; Park HJ
J Atheroscler Thromb; 2014; 21(1):23-37. PubMed ID: 24088646
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Hong Q; Ma ZC; Huang H; Wang YG; Tan HL; Xiao CR; Liang QD; Zhang HT; Gao Y
Eur J Pharmacol; 2016 Apr; 777():1-8. PubMed ID: 26948317
[TBL] [Abstract][Full Text] [Related]
14. p-Terphenyl curtisian E inhibits in vitro platelet aggregation via cAMP elevation and VASP phosphorylation.
Kamruzzaman SM; Yayeh T; Ji HD; Park JY; Kwon YS; Lee IK; Kim S; Oh SH; Kim SD; Roh SS; Yun BS; Rhee MH
Vascul Pharmacol; 2013; 59(3-4):83-9. PubMed ID: 23872194
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.
Sogo N; Magid KS; Shaw CA; Webb DJ; Megson IL
Biochem Biophys Res Commun; 2000 Dec; 279(2):412-9. PubMed ID: 11118301
[TBL] [Abstract][Full Text] [Related]
16. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function.
Aszódi A; Pfeifer A; Ahmad M; Glauner M; Zhou XH; Ny L; Andersson KE; Kehrel B; Offermanns S; Fässler R
EMBO J; 1999 Jan; 18(1):37-48. PubMed ID: 9878048
[TBL] [Abstract][Full Text] [Related]
17. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase.
Chang CC; Lu WJ; Chiang CW; Jayakumar T; Ong ET; Hsiao G; Fong TH; Chou DS; Sheu JR
J Nutr Biochem; 2010 Dec; 21(12):1214-21. PubMed ID: 20015631
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
Gordge MP; Hothersall JS; Noronha-Dutra AA
Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
[TBL] [Abstract][Full Text] [Related]
19. An ex vivo standardized assay to measure human platelet cGMP.
di Villa Bianca Rd; Mitidieri E; Mirone V; Fusco F; Imbimbo C; Cirino G; Sorrentino R
J Pharmacol Toxicol Methods; 2011; 64(2):164-7. PubMed ID: 21801844
[TBL] [Abstract][Full Text] [Related]
20. The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets.
Kobsar A; Koessler J; Kehrer L; Gambaryan S; Walter U
Thromb Haemost; 2012 Mar; 107(3):521-9. PubMed ID: 22234363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]